What patient details are needed to give a specific recommendation for oral contraceptive use?

Essential Patient Information for Oral Contraceptive Prescribing

To safely prescribe oral contraceptives, you must obtain specific information about medical conditions that affect eligibility (U.S. MEC categories), current medications that interact with hormonal contraceptives, reproductive history including breastfeeding status and timing since last menstrual period, and measure blood pressure for combined hormonal contraceptives. 1, 2

Critical Medical History Components

Absolute Contraindications to Assess (Category 4 - Unacceptable Health Risk)

When evaluating a patient for combined oral contraceptives (COCs), you must specifically ask about and rule out:

• Cardiovascular conditions:

  • Current or history of deep venous thrombosis (DVT) or pulmonary embolism (PE), particularly if not on anticoagulation therapy 1
  • Multiple cardiovascular risk factors (smoking, diabetes, hypertension combined)
  • History of stroke or ischemic heart disease

• Breastfeeding status: COCs are category 4 if <1 month postpartum while breastfeeding, and category 3 if 1-6 months postpartum while breastfeeding 1

• Postpartum timing: Combined hormonal contraceptives carry higher thrombotic risk if started <21 days postpartum 1

Drug Interactions Requiring Alternative Methods

You must specifically ask about these medications that reduce contraceptive efficacy:

• Anticonvulsants: Phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine (Category 3 for COCs and POPs) 2
• Rifampin or rifabutin: Category 3 for combined hormonal contraceptives and progestin-only pills 2
• Antiretroviral therapy: Multiple interactions exist; ritonavir-boosted protease inhibitors have varying categories 2
• St. John's wort: Category 2 for both combined and progestin-only methods 2

Important caveat: Lamotrigine levels may be reduced by COCs (Category 3), but progestin-only methods are Category 1 2. Broad-spectrum antibiotics do NOT reduce contraceptive efficacy 2.

Timing and Initiation Requirements

Information Needed for Safe Initiation

Last menstrual period timing determines need for backup contraception:

• Combined hormonal contraceptives: Can start anytime if reasonably certain patient is not pregnant. If started >5 days after menses began, backup contraception (condoms) needed for 7 days 2

• Progestin-only pills (norethindrone/norgestrel): If started >5 days after menses, backup needed for 2 days 2

• Drospirenone POP: If started >1 day after menses, backup needed for 7 days 2

Pregnancy Exclusion

Before initiating any hormonal contraceptive, you must be "reasonably certain" the patient is not pregnant 3, 2. This requires:

• Timing since last menstrual period
• Recent sexual activity history
• Current contraceptive use
• Pregnancy symptoms

Required Physical Examination Elements

The examination requirements differ by method type:

• Combined hormonal contraceptives: Blood pressure measurement is required before initiation 2
• Progestin-only pills: No examination required 2
• IUDs: Bimanual examination and cervical inspection required 2

Critical point: A full pelvic examination is NOT required before initiating oral contraceptives 2. This removes an unnecessary barrier to contraceptive access.

Age and Reproductive History

Adolescents and Young Women

Oral contraceptives can be used by women of all ages 3. However, adolescents may benefit from more frequent follow-up to assess satisfaction and adherence 3.

Postpartum Considerations

Specific timing matters:

• Breastfeeding women:

  • POPs can be started immediately postpartum (Category 2 if <1 month, Category 1 if ≥1 month) 3
  • COCs should be avoided until ≥6 months postpartum (Category 3 before 6 months) 1

• Non-breastfeeding women:

  • POPs can be started immediately (Category 1) 3
  • If ≥21 days postpartum without return of menses, backup contraception needed for 2 days 3

Medication Selection Considerations

Patient Preference Factors

Ask about:

• Bleeding preferences: Does the patient want monthly withdrawal bleeding or continuous use? 3
• Adherence concerns: Daily pill-taking ability affects whether POPs (requiring strict timing) or COCs are more appropriate 3
• Side effect tolerance: History of hormonal contraceptive side effects guides formulation choice

Formulation Selection

Start with the lowest effective dose - typically 30-35 mcg ethinyl estradiol for combined pills 4, 5. Higher doses (50 mcg) may be needed only if breakthrough bleeding persists beyond initial cycles 5.

For progestin-only pills: Timing strictness differs:

• Traditional POPs (norethindrone): Considered missed if >3 hours late 3
• Drospirenone POP: Has a 24-hour window (newer formulation)

Follow-Up and Monitoring

No routine follow-up visit is required after POP initiation 3. However, advise patients to return if:

• Side effects are problematic
• They want to change methods
• Warning signs develop

At subsequent routine visits, assess:

• Satisfaction with method
• Changes in health status or medications that would change U.S. MEC category
• Weight changes if patient is concerned 3

Common Pitfalls to Avoid

1. Don't require unnecessary examinations: Pelvic exams are not needed for oral contraceptive initiation 2

2. Don't forget drug interactions: Specifically ask about anticonvulsants and rifampin, not just "all medications" 2

3. Don't overlook postpartum timing: The thrombotic risk window is critical in the first 21 days postpartum 1

4. Don't assume all antibiotics interact: Only rifampin/rifabutin reduce efficacy; broad-spectrum antibiotics do not 2

5. Don't miss the breastfeeding window: COC use while breastfeeding <6 months postpartum is Category 3 1